Description

CJC-1295 with DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide designed to stimulate the production and release of growth hormone by increasing the half-life of growth hormone-releasing hormone (GHRH) analogs. CJC-1295 is a modification of the first 29 amino acids of Growth Hormone Releasing Hormone.  This modification allows for extended activity, resulting in more sustained and stable levels of growth hormone secretion.

Research Applications
CJC-1295 with DAC is widely studied for its potential role in:

• Enhancing protein synthesis and cellular growth.
• Promoting recovery in tissue repair and regeneration studies.
• Supporting metabolic research related to fat loss and lean muscle preservation.
• Investigating anti-aging mechanisms through improved growth hormone levels.

Key Features

• Extended half-life in the bloodstream due to DAC technology.
• Improved stability for long-term studies.
• Designed for in-vitro research purposes only.

Important Notes
CJC-1295 with DAC is strictly intended for laboratory research and in-vitro experimentation. It is not for human or animal use. This product is not FDA-approved for the diagnosis, treatment, prevention, or cure of any disease or condition.